{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T10:14:51Z","timestamp":1783678491254,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"REI: Red de Enfermedades Inflamatorias","award":["RD24\/0007\/0017"],"award-info":[{"award-number":["RD24\/0007\/0017"]}]},{"name":"Ministerio de Ciencia e Innovaci\u00f3n (Proyectos de generaci\u00f3n de conocimiento)-Fondo Europeo de Desarrollo Regional","award":["PID2021-126041OB-I00"],"award-info":[{"award-number":["PID2021-126041OB-I00"]}]},{"name":"Esclerosis M\u00faltiple Espa\u00f1a\u201d"},{"DOI":"10.13039\/501100009589","name":"Fundaci\u00f3n LAIR","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009589","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-46208-3","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T18:47:49Z","timestamp":1774637269000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Differential distribution of antiviral serology across multiple sclerosis phenotypes and its implications for disease pathogenesis"],"prefix":"10.1038","volume":"16","author":[{"given":"Maria Inmaculada","family":"Dominguez-Mozo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ruberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Rodr\u00edguez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa Mar\u00eda","family":"Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucienne","family":"Costa-Frossard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Villarrubia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Aladro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Casanova-Pe\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luisa","family":"Mart\u00ednez-Gin\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Manuel","family":"Garc\u00eda-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Ortega-Madue\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Alonso-Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guadalupe","family":"P\u00e9rez de Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Angel","family":"Garcia-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Alvarez-Lafuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"46208_CR1","doi-asserted-by":"publisher","first-page":"e214141","DOI":"10.1212\/WNL.0000000000214141","volume":"105","author":"N Sahi","year":"2025","unstructured":"Sahi, N., Ciccarelli, O., Houlden, H. & Chard, D. T. Unlocking multiple sclerosis genetics: from susceptibility to severity. Neurology 105, e214141 (2025).","journal-title":"Neurology"},{"key":"46208_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00284-022-03112-z","volume":"80","author":"S Sedighi","year":"2022","unstructured":"Sedighi, S. et al. Comprehensive investigations relationship between viral infections and multiple sclerosis pathogenesis. Curr. Microbiol. 80, 15 (2022).","journal-title":"Curr. Microbiol."},{"key":"46208_CR3","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.abj8222","volume":"375","author":"K Bjornevik","year":"2022","unstructured":"Bjornevik, K. et al. Longitudinal analysis reveals high prevalence of Epstein\u2013Barr virus associated with multiple sclerosis. Science 375, 296\u2013301 (2022).","journal-title":"Science"},{"key":"46208_CR4","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1177\/1352458518823940","volume":"25","author":"M Marrodan","year":"2019","unstructured":"Marrodan, M., Alessandro, L., Farez, M. F. & Correale, J. The role of infections in multiple sclerosis. Mult Scler. 25, 891\u2013901 (2019).","journal-title":"Mult Scler."},{"key":"46208_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3390\/pathogens13060499","volume":"13","author":"PA Maple","year":"2024","unstructured":"Maple, P. A. et al. Epstein\u2013Barr virus, herpes simplex virus, and varicella zoster virus infection dynamics in people with multiple sclerosis from Northern Italy. Pathogens 13, 499 (2024). Cytomegalovirus.","journal-title":"Pathogens"},{"key":"46208_CR6","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3390\/v12060643","volume":"12","author":"RE Tarlinton","year":"2020","unstructured":"Tarlinton, R. E., Martynova, E., Rizvanov, A. A., Khaiboullina, S. & Verma, S. Role of viruses in the pathogenesis of multiple sclerosis. Viruses 12, 643 (2020).","journal-title":"Viruses"},{"key":"46208_CR7","doi-asserted-by":"publisher","first-page":"577636","DOI":"10.1016\/j.jneuroim.2021.577636","volume":"358","author":"S Jakhmola","year":"2021","unstructured":"Jakhmola, S. et al. Herpesviruses and the hidden links to multiple sclerosis neuropathology. J. Neuroimmunol. 358, 577636 (2021).","journal-title":"J. Neuroimmunol."},{"key":"46208_CR8","doi-asserted-by":"publisher","first-page":"e0192109","DOI":"10.1371\/journal.pone.0192109","volume":"13","author":"A Hassani","year":"2018","unstructured":"Hassani, A., Corboy, J. R., Al-Salam, S. & Khan, G. Epstein\u2013Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells. PLoS One. 13, e0192109 (2018).","journal-title":"PLoS One"},{"key":"46208_CR9","doi-asserted-by":"publisher","first-page":"e104836","DOI":"10.1371\/journal.pone.0104836","volume":"9","author":"I Ortega-Madue\u00f1o","year":"2014","unstructured":"Ortega-Madue\u00f1o, I. et al. Anti-human herpesvirus 6A\/B IgG correlates with relapses and progression in multiple sclerosis. PLoS One. 9, e104836 (2014).","journal-title":"PLoS One"},{"key":"46208_CR10","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","volume":"21","author":"P Benkert","year":"2022","unstructured":"Benkert, P. et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol. 21, 246\u2013257 (2022).","journal-title":"Lancet Neurol."},{"key":"46208_CR11","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1179\/016164106X98134","volume":"28","author":"R Zivadinov","year":"2006","unstructured":"Zivadinov, R. et al. Positivity of cytomegalovirus antibodies predicts a better clinical and radiological outcome in multiple sclerosis patients. Neurol. Res. 28, 262\u2013269 (2006).","journal-title":"Neurol. Res."},{"key":"46208_CR12","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1111\/ene.14961","volume":"28","author":"V Grut","year":"2021","unstructured":"Grut, V. et al. Cytomegalovirus seropositivity is associated with reduced risk of multiple sclerosis: a presymptomatic case\u2013control study. Eur. J. Neurol. 28, 3072\u20133079 (2021).","journal-title":"Eur. J. Neurol."},{"key":"46208_CR13","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jamaneurol.2025.1481","volume":"82","author":"N Fissolo","year":"2025","unstructured":"Fissolo, N. et al. Prognostic factors for multiple sclerosis symptoms in radiologically isolated syndrome. JAMA Neurol. 82, 722\u2013733 (2025).","journal-title":"JAMA Neurol."},{"key":"46208_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s00415-024-12763-w","volume":"272","author":"M Comabella","year":"2024","unstructured":"Comabella, M. et al. Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis. J. Neurol. 272, 26 (2024).","journal-title":"J. Neurol."},{"key":"46208_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/1352458513494489","volume":"20","author":"E Sundqvist","year":"2014","unstructured":"Sundqvist, E. et al. Cytomegalovirus seropositivity is negatively associated with multiple sclerosis. Mult Scler. 20, 165\u2013173 (2014).","journal-title":"Mult Scler."},{"key":"46208_CR16","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1177\/1352458515601215","volume":"22","author":"JE Mart\u00ednez-Rodr\u00edguez","year":"2016","unstructured":"Mart\u00ednez-Rodr\u00edguez, J. E. et al. Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis. Mult Scler. J. 22, 741\u2013752 (2016).","journal-title":"Mult Scler. J."},{"key":"46208_CR17","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.3389\/fimmu.2019.02403","volume":"10","author":"A Moreira","year":"2019","unstructured":"Moreira, A. et al. Adaptive features of natural killer cells in multiple sclerosis. Front. Immunol. 10, 2403 (2019).","journal-title":"Front. Immunol."},{"key":"46208_CR18","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1016\/j.cell.2023.11.015","volume":"186","author":"H Vietzen","year":"2023","unstructured":"Vietzen, H. et al. Ineffective control of Epstein\u2013Barr virus-induced autoimmunity increases the risk for multiple sclerosis. Cell 186, 5705\u20135718e13 (2023).","journal-title":"Cell"},{"key":"46208_CR19","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3390\/ijms25020753","volume":"25","author":"L M\u00fcller","year":"2024","unstructured":"M\u00fcller, L. & Di Benedetto, S. Immunosenescence and cytomegalovirus: exploring their connection in the context of aging, health, and disease. Int. J. Mol. Sci. 25, 753 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"46208_CR20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.4049\/jimmunol.1301384","volume":"192","author":"C Wang","year":"2014","unstructured":"Wang, C. et al. Effects of aging, cytomegalovirus infection, and EBV infection on human B cell repertoires. J. Immunol. 192, 603\u2013611 (2014).","journal-title":"J. Immunol."},{"key":"46208_CR21","doi-asserted-by":"publisher","first-page":"991662","DOI":"10.3389\/fimmu.2022.991662","volume":"13","author":"MI Dom\u00ednguez-Mozo","year":"2022","unstructured":"Dom\u00ednguez-Mozo, M. I. et al. Epstein\u2013Barr virus and multiple sclerosis in a Spanish cohort: a two-years longitudinal study. Front. Immunol. 13, 991662 (2022).","journal-title":"Front. Immunol."},{"key":"46208_CR22","doi-asserted-by":"publisher","first-page":"104747","DOI":"10.1016\/j.msard.2023.104747","volume":"76","author":"JG Pereira","year":"2023","unstructured":"Pereira, J. G. et al. Higher frequency of human herpesvirus-6 viral DNA simultaneously with low frequency of Epstein\u2013Barr virus viral DNA in a cohort of multiple sclerosis patients from Rio de Janeiro, Brazil. Mult Scler. Relat. Disord. 76, 104747 (2023).","journal-title":"Mult Scler. Relat. Disord"},{"key":"46208_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1212\/WNL.0b013e3181aa29fe","volume":"73","author":"RA Farrell","year":"2009","unstructured":"Farrell, R. A. et al. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology 73, 32\u201338 (2009).","journal-title":"Neurology"},{"key":"46208_CR24","doi-asserted-by":"publisher","first-page":"817238","DOI":"10.1155\/2015\/817238","volume":"2015","author":"KA McKay","year":"2015","unstructured":"McKay, K. A., Kwan, V., Duggan, T. & Tremlett, H. Risk factors associated with the onset of relapsing\u2013remitting and primary progressive multiple sclerosis: a systematic review. Biomed. Res. Int. 2015, 817238 (2015).","journal-title":"Biomed. Res. Int."},{"key":"46208_CR25","doi-asserted-by":"publisher","first-page":"1385233","DOI":"10.3389\/fnins.2024.1385233","volume":"18","author":"S Agostini","year":"2024","unstructured":"Agostini, S. et al. EBV and multiple sclerosis: expression of LMP2A in MS patients. Front. Neurosci. 18, 1385233 (2024).","journal-title":"Front. Neurosci."},{"key":"46208_CR26","doi-asserted-by":"publisher","first-page":"e2425670122","DOI":"10.1073\/pnas.2425670122","volume":"122","author":"N Orr","year":"2025","unstructured":"Orr, N. & Steinman, L. Epstein\u2013Barr virus and the immune microenvironment in multiple sclerosis: insights from high-dimensional brain tissue imaging. Proc. Natl Acad. Sci. U.S.A. 122, e2425670122 (2025).","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"46208_CR27","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1177\/13524585241274571","volume":"30","author":"JD L\u00fcnemann","year":"2024","unstructured":"L\u00fcnemann, J. D. et al. Cytomegalovirus immune responses are associated with lower serum neurofilament light chain and disability accumulation risk at multiple sclerosis onset. Mult Scler. 30, 1445\u20131454 (2024).","journal-title":"Mult Scler."},{"key":"46208_CR28","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.3389\/fimmu.2019.02715","volume":"10","author":"E Engdahl","year":"2019","unstructured":"Engdahl, E. et al. Increased serological response against human herpesvirus 6A is associated with risk for multiple sclerosis. Front. Immunol. 10, 2715 (2019).","journal-title":"Front. Immunol."},{"key":"46208_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/brain\/awad374","volume":"147","author":"V Grut","year":"2023","unstructured":"Grut, V. et al. Human herpesvirus-6A and axonal injury before the clinical onset of multiple sclerosis. Brain 147, 177\u2013185 (2023).","journal-title":"Brain"},{"key":"46208_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12883-022-02568-7","volume":"22","author":"KI Voumvourakis","year":"2022","unstructured":"Voumvourakis, K. I. et al. Human herpesvirus 6 infection as a trigger of multiple sclerosis: an update of recent literature. BMC Neurol. 22, 57 (2022).","journal-title":"BMC Neurol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46208-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46208-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46208-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T09:32:54Z","timestamp":1783675974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46208-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["46208"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-46208-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this Article was revised: In the original version of this Article, the authors Mar\u00eda Inmaculada Dominguez-Mozo and Roberto Alvarez-Lafuente were incorrectly indexed. The original Article has been corrected.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mar\u00eda Inmaculada Dom\u00ednguez-Mozo: nothing to disclose.Stefano Ruberto: nothing to disclose.Carla Rodr\u00edguez-Garc\u00eda: nothing to disclose.Luisa Mar\u00eda Villar: has served at scientific advisory boards, participated in meetings sponsored by, received speaking honoraria or travel funding or research grants from Roche, Sanofi, Merck, Biogen, Bristol Myers, and Novartis.Lucienne Costa-Frossard: reports compensation for consulting services and speaker honoraria from Biogen, Bristol Myers Squibb, Janssen, Merck-Serono, Novartis, Sanofi, Roche, and Teva.Noelia Villarrubia: nothing to disclose.Yolanda Aladro: has received research grants, travel support and lecturing and consulting fees from: Teva, Biogen, Roche, Merck, Novartis, Almirall, Sanofi-Genzime, Janssen and Bristol Myers Squibb.Ignacio Casanova-Pe\u00f1o: has received payments for consulting services from Novartis and Merck, speaking honoraria from Merck, Novartis, Sanofi, and Neuraxpharm, support for attending meetings from Merck, and research grants from TEVA and Sanofi.Mar\u00eda Luisa Mart\u00ednez-Gin\u00e9s: has received compensation for consulting services and speaking fees from Merck, Biogen, Novartis, Sanofi-Genzyme, Almirall, ROCHE, BMS, Juvis\u00e9 and TEVA.Jose Manuel Garc\u00eda-Dom\u00ednguez: has received speaker honoraria, research grants or advisor invitations from Bristol-Myers-Squibb, Johnson and Johnson, Biogen, Sanofi, Almirall, Merck, Roche, Zenas Pharma and Novartis.Isabel Ortega Madue\u00f1o: nothing to disclose.Andrea Alonso Garrido: nothing to disclose.Guadalupe P\u00e9rez de Villar: nothing to disclose.Mar\u00eda \u00c1ngel Garc\u00eda-Mart\u00ednez: nothing to disclose.Rafael Arroyo: has been a speaker or has participated in the advisory board of Novartis, Teva, Roche, Bristol, Janssem, Biogen, Merck and Sanofi-Genzyme.Roberto \u00c1lvarez-Lafuente: has received support for attending meetings from Biogen, Merck, Novartis, Sanofi-Genzyme and Neuraxpharm.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10929"}}